Rho GTPase activating protein 45Genealiases: HA-1 · HLA-HA1 · HMHA1
Q-omics provides the consensus-scored ARHGAP45 profile across patient tissues and cancer cell-line models. ARHGAP45 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP45 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ARHGAP45 protein abundance shows 27,025 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ARHGAP45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP45 survival associations across molecular data types. ARHGAP45 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP45 RNA expression–survival associations across cancer types. High ARHGAP45 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in HNSC, UCEC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ARHGAP45 RNA expression.
This table summarizes ARHGAP45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP45 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, KIRP, LIHC and STAD. The KIRC box plot shows higher ARHGAP45 RNA expression in tumor versus normal tissue (log2 FC = +1.504, t-test p < 0.001).
This table shows molecular features associated with ARHGAP45 in patient tissues and cancer cell lines. In patient samples, ARHGAP45 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
